Stockholm, Sweden — Medivir AB (OMX: MVIR) today announces that the Annual
Report for 2013 now is available at the company’s website: www.medivir.com.


Annual Report 2013

http://www.medivir.se/v5/images/pdf/2014/Medivir_2013_ENG.pdf


“2013 was, without doubt, one of the most eventful years in Medivir’s 25-year
history! The biggest single event during the year was the marketing approval of
simeprevir – a pharmaceutical for the treatment of patients with chronic
hepatitis C that we have helped develop. The approval has allowed the launch of
simeprevir in Japan, Canada and the USA. Hepatitis C infected patients can now
be treated using a drug that we have helped discover and develop. It is a source
of great satisfaction to all Medivir employees, myself included, that we have
developed a pharmaceutical all the way from a concept to a new treatment that
can cure people and save lives,” said Medivir’s CEO, Maris Hartmanis, in his
CEO’s Statement in this year’s Annual Report.”


About Medivir
Medivir is an emerging research-based pharmaceutical company focused on
infectious diseases. Medivir has world class expertise in polymerase and
protease drug targets and drug development which has resulted in a strong
infectious disease R&D portfolio. The Company’s key pipeline asset is
simeprevir, a novel protease inhibitor for the treatment of hepatitis C that is
being developed in collaboration with Janssen R&D Ireland. The company is also
working with research and development in other areas, such as bone disorders and
neuropathic pain. Medivir has also a broad product portfolio with prescription
pharmaceuticals in the Nordics.